Safety of intracameral cefuroxime in pars plana vitrectomy

Retinal toxicity secondary to subconjunctival cefuroxime following pars plana vitrectomy: A case report and literature review

“…Other factors that may theoretically increase the risk of toxicity include small eyes, sclerotomy leak and the use of intraocular tamponade. 10 This case highlights the need to consider cefuroxime toxicity in patients presenting with unexplained post-PPV visual loss.…”

“…Other factors affecting intraocular drug concentration after subconjunctival delivery include volume injected and in the context of PPV, the presence of sclerotomy leak, intraocular tamponade and ocular size. 10 This may support using commercially prepared intracameral cefuroxime formulations as endophthalmitis prophylaxis for pars plana vitrectomy to provide a more consistent intraocular concentration with a lower risk of toxicity. It is important though to note that intracameral cefuroxime does carry a risk of toxicity if a dilution error occurs.…”

A Novel Postoperative Drop Regimen Reduces Risk of Ocular Hypertension Following Pars Plana Vitrectomy

“…All PPVs were conducted using three 25 G valved ports and the Constellation Vision System (Alcon, Fort Worth, TX, USA) by one of six surgeons. All cases received intracameral cefuroxime [14] and subconjunctival dexamethasone 4 mg as final surgical steps. Both primary and secondary PPVs were included, as were those surgeries in which PPV was combined with additional operative procedures such as phacoemulsification, primary or secondary intraocular lens insertion, or scleral buckling.…”